Abate-Daga, D., Rosenberg, S. A., & Morgan, R. A. (2014). Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies. Oncoimmunology, 3, e29194.

Article  PubMed  PubMed Central  Google Scholar 

Alzubi, J., Dettmer-Monaco, V., Kuehle, J., Thorausch, N., Seidl, M., Taromi, S., Schamel, W., Zeiser, R., Abken, H., Cathomen, T., et al. (2020). PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model. Molecular Therapy Oncolytics, 18, 226–235.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bates, P. D., Rakhmilevich, A. L., Cho, M. M., Bouchlaka, M. N., Rao, S. L., Hales, J. M., Orentas, R. J., Fry, T. J., Gilles, S. D., Sondel, P. M., et al. (2021). combining immunocytokine and ex vivo activated NK cells as a platform for enhancing graft-versus-tumor effects against GD2+ murine neuroblastoma. Frontiers in Immunology, 12, 668307.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beckett, A. N., Chockley, P., Pruett-Miller, S. M., Nguyen, P., Vogel, P., Sheppard, H., Krenciute, G., Gottschalk, S., & DeRenzo, C. (2023). CD47 expression is critical for CAR T-cell survival in vivo. Journal for Immunotherapy of Cancer, 11, e005857.

Article  PubMed  PubMed Central  Google Scholar 

Bielamowicz, K., Fousek, K., Byrd, T. T., Samaha, H., Mukherjee, M., Aware, N., Wu, M. F., Orange, J. S., Sumazin, P., Man, T. K., et al. (2018). Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro-Oncology, 20, 506–518.

Article  CAS  PubMed  Google Scholar 

Candas-Green, D., Xie, B., Huang, J., Fan, M., Wang, A., Menaa, C., Zhang, Y., Zhang, L., Jing, D., Azghadi, S., et al. (2020). Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nature Communications, 11, 4591.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen, K. H., Wada, M., Pinz, K. G., Liu, H., Shuai, X., Chen, X., Yan, L. E., Petrov, J. C., Salman, H., Senzel, L., Leung, E. L. H., et al. (2018). A compound chimeric antigen receptor strategy for targeting multiple myeloma. Leukemia, 32, 402–412.

Article  CAS  PubMed  Google Scholar 

Chen, C., Gu, Y. M., Zhang, F., Zhang, Z. C., Zhang, Y. T., He, Y. D., Wang, L., Zhou, N., Tang, F. T., Liu, H. J., et al. (2021). Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. Oncoimmunology, 10, 1901434.

Article  PubMed  PubMed Central  Google Scholar 

Daneshmanesh, A. H., Mikaelsson, E., Jeddi-Tehrani, M., Bayat, A. A., Ghods, R., Ostadkarampour, M., Akhondi, M., Lagercrantz, S., Larsson, C., Osterborg, A., et al. (2008). Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. International Journal of Cancer, 123, 1190–1195.

Article  CAS  PubMed  Google Scholar 

Dréau, D., Moore, L. J., Wu, M., Roy, L. D., Dillion, L., Porter, T., Puri, R., Momin, N., Wittrup, K. D., & Mukherjee, P. (2019). Combining the specific anti-MUC1 antibody TAB004 and Lip-MSA-IL-2 limits pancreatic cancer progression in immune competent murine models of pancreatic ductal adenocarcinoma. Frontiers in Oncology, 9, 330.

Article  PubMed  PubMed Central  Google Scholar 

Fousek, K., Watanabe, J., Joseph, S. K., George, A., An, X., Byrd, T. T., Morris, J. S., Luong, A., Martínez-Paniagua, M. A., Sanber, K., et al. (2021). CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia, 35, 75–89.

Article  CAS  PubMed  Google Scholar 

Friedman, K. M., Garrett, T. E., Evans, J. W., Horton, H. M., Latimer, H. J., Seidel, S. L., Horvath, C. J., & Morgan, R. A. (2018). Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Human Gene Therapy, 29, 585–601.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018). CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine, 24, 20–28.

Article  CAS  PubMed  Google Scholar 

Ghartey-Kwansah, G., Li, Z., Feng, R., Wang, L., Zhou, X., Chen, F. Z., Xu, M. M., Jones, O., Mu, Y., Chen, S., et al. (2018). Comparative analysis of FKBP family protein: Evaluation, structure, and function in mammals and Drosophila melanogaster. BMC Developmental Biology, 18, 7.

Article  PubMed  PubMed Central  Google Scholar 

Gill, S., & June, C. H. (2015). Going viral: Chimeric antigen receptor T-cell therapy for hematological malignancies. Immunological Reviews, 263, 68–89.

Article  CAS  PubMed  Google Scholar 

Golubovskaya, V., Berahovich, R., Zhou, H., Xu, S., Harto, H., Li, L., Chao, C. C., Mao, M. M., & Wu, L. (2017). CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth. Cancers, 9, 139.

Article  PubMed  PubMed Central  Google Scholar 

Guo, F., & Cui, J. (2020). CAR-T in solid tumors: Blazing a new trail through the brambles. Life Sciences, 260, 118300.

Article  CAS  PubMed  Google Scholar 

Hashem Boroojerdi, M., Rahbarizadeh, F., Safarzadeh Kozani, P., Kamali, E., & Safarzadeh Kozani, P. (2020). Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia. Medical Oncology, 37, 100.

Article  CAS  PubMed  Google Scholar 

Jiang, H., Shi, Z., Wang, P., Wang, C., Yang, L., Du, G., Zhang, H., Shi, B., Jia, J., Li, Q., Wang, H., & Li, Z. (2019). Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. Journal of the National Cancer Institute, 111, 409–418.

Article  PubMed  Google Scholar 

Jiang, V. C., Liu, Y., Jordan, A., McIntosh, J., Li, Y., Che, Y., Jessen, K. A., Lannutti, B. J., & Wang, M. (2021a). The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. Journal of Hematology & Oncology, 14, 132.

Article  CAS  Google Scholar 

Jiang, W., Li, T., Guo, J., Wang, J., Jia, L., Shi, X., Yang, T., Jiao, R., Wei, X., Feng, Z., et al. (2021b). Bispecific c-Met/PD-L1 CAR-T cells have enhanced therapeutic effects on hepatocellular carcinoma. Frontiers in Oncology, 11, 546586.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang, Z., Sun, H., Yu, J., Tian, W., & Song, Y. (2021c). Targeting CD47 for cancer immunotherapy. Journal of Hematology & Oncology, 14, 180.

Article  CAS  Google Scholar 

Jin, L., Ge, H., Long, Y., Yang, C., Chang, Y. E., Mu, L., Sayour, E. J., De Leon, G., Wang, Q. J., Yang, J. C., et al. (2018). CD70, a novel target of CAR T-cell therapy for gliomas. Neuro-Oncology, 20, 55–65.

Article  CAS  PubMed  Google Scholar 

Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A. K., Dentchev, T., Thekkat, P., Loew, A., et al. (2015). Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Science Translational Medicine, 7, 275ra22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

June, C. H., & Sadelain, M. (2018). Chimeric antigen receptor therapy. The New England Journal of Medicine, 379, 64–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jung, M., Yang, Y., McCloskey, J. E., Zaman, M., Vedvyas, Y., Zhang, X., Stefanova, D., Gray, K. D., Min, I. M., Zarnegar, R., et al. (2020). Chimeric antigen receptor T cell therapy targeting ICAM-1 in gastric cancer. Molecular Therapy Oncolytics, 18, 587–601.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karimi, M. A., Lee, E., Bachmann, M. H., Salicioni, A. M., Behrens, E. M., Kambayashi, T., & Baldwin, C. L. (2014). Measuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay. PLoS ONE, 9, e89357.

Article  PubMed  PubMed Central  Google Scholar 

Kusakawa, S., Machida, K., Yasuda, S., Takada, N., Kuroda, T., Sawada, R., Okura, H., Tsutsumi, H., Kawamata, S., & Sato, Y. (2015). Characterization of in vivo tumorigenicity tests using severe immunodeficient NOD/Shi-scid IL2Rγnull mice for detection of tumorigenic cellular impurities in human cell-processed therapeutic products. Regenerative Therapy, 1, 30–37.

Article  PubMed